FutureMeds, Europe’s leading independent site network specialising in decentralised clinical trials, has been recognized among Britain’s 100 fastest‑growing private companies by The Sunday Times 100, underscoring its exceptional growth trajectory (with 96.73% annual growth over the last 3 years) and operational excellence.
Backed by HGL Private Capital since 2021, FutureMeds embarked on a strategic “buy‑and‑build” approach and accelerated organic expansion across Europe. In just four years, the company has grown significantly—from 6 sites in 2021 to over 24 locations spanning the UK, Poland, Germany, Spain, Bulgaria and Ukraine. This rapid rollout reflects HGL’s confidence in FutureMeds’ robust clinical‑trials model and its commitment to patient-centric innovation.
“Being named in The Sunday Times 100 is a powerful validation of our strategy,” said Dr.Radoslaw Janice (FutureMeds CEO). “With HGL’s partnership, we’ve combined targeted acquisitions with patient‑focused organic growth, creating a pan‑European platform that delivers high‑quality clinical data and enhances sponsor confidence.”
Ged Gould, Co-founder of HGL Private Capital, commented: “Congratulations to the entire FutureMeds team on this well deserved recognition. From the outset we believed in their vision to transform clinical trial delivery across Europe. Their passion, pace, and patient-first mindset have been central to this remarkable growth. We are proud to support their journey and excited about for what lies ahead.”
HGL Private Capital’s investment has enabled key site acquisitions and bolstered FutureMeds’ technological deployment, supporting sponsors and CROs with:
- Streamlined trial recruitment through local expertise and investigator networks
- Scalable decentralised clinical trial (DCT) delivery
- Strategic geographical expansion, entering high‑potential markets like Germany, Spain and Bulgaria and reaching top enrolment rankings in focus areas like osteoporosis, cardiovascular, COVID‑19 and vaccines
As FutureMeds looks ahead, the company is poised to continue its growth journey, with future site openings and acquisitions as well as DCT innovations in the pipeline—well-aligned with HGL’s growth capital and operational expertise.
About HGL Private Capital
HGL Private Capital is a specialist growth‑oriented investor focused on partnering with management teams to scale high-potential companies. HGL focuses on equity investments of up to £10 million, including management buyouts, cash-out deals and funding for growth strategies.
About FutureMeds
Founded as an independent site network, FutureMeds operates 24 research sites across 18 countries, enrolling tens of thousands of patients annually. The company leads in delivering decentralised and hybrid clinical trials with precision patient engagement and streamlined delivery.
This announcement highlights how HGL’s investment and strategic guidance helped propel FutureMeds into the Sunday Times 100, showcasing a clear success story of organic and M&A-driven growth in the clinical trial industry.
